Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based Sorrento Therapeutics has completed patient enrollment in its ongoing TRIBECA (TRIal establishing bioequivalence [BE] between Cynviloq and Albumin-bound paclitaxel) registrational trial.
Subscribe to our email newsletter
In the trial, a total of 111 patients were enrolled globally from sites in the US, Eastern Europe and Asia.
The company said that data, secured from the ongoing safety assessment from treated patients, is consistent with the toxicity profile reported in the literature with albumin-bound paclitaxel.
Earlier, the company reported positive pharmacokinetic (PK) data from the first eight patients enrolled in the TRIBECA study.
In March 2014, the company started registrational trial of Cynviloq, the next-generation nanoparticle paclitaxel, and is currently under the abbreviated 505(b)(2) regulatory pathway.
Currently, resiniferatoxin (RTX), a non-opiate TRPV1 agonist, is being developed by the company in a Phase I/II trial at the NIH to treat terminal cancer patients suffering from intractable pain.
Recently, the company signed a definitive agreement with NantWorks to form a global joint venture called ‘The Immunotherapy Antibody JV’, which will focus on next generation cancer and autoimmune diseases immunotherapies.
The company has also entered into a definitive agreement with an immuno-oncology firm Conkwest to jointly develop next generation Chimeric Antigen Receptor Tumor-attacking Neukoplast (CAR.TNK) immunotherapies to treat cancer.
The CAR.TNK technology platform combines Conkwest’s Neukoplast cell line with Sorrento’s proprietary G-MAB fully human antibody technology and CAR designs to further improve the potency and targeting of Neukoplast.